Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 4INTERVENTIONAL

Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention

Comparison Between the Efficacy of Rivaroxaban vs Enoxaparin in Post-Operative Deep Venous Thrombosis Prophylaxis After Exploratory Laparotomy

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this clinical trial is to learn if rivaroxaban works better than enoxaparin to prevent deep vein thrombosis (DVT) after emergency exploratory laparotomy in adults. It will also learn about the safety of rivaroxaban compared to enoxaparin. The main questions it aims to answer are: Does rivaroxaban lower the number of patients who develop DVT after exploratory laparotomy compared to enoxaparin? What medical problems or side effects do participants have when taking rivaroxaban versus enoxaparin? Researchers will compare rivaroxaban (an oral anticoagulant) to enoxaparin (a subcutaneous injection) to see which drug works better to prevent blood clots after surgery. Participants will: Take rivaroxaban 10 mg orally once daily for 7 days, or enoxaparin 40 mg subcutaneously once daily for 7 days after surgery Undergo duplex color Doppler ultrasound scans of the legs on day 5 and day 10 after surgery Be monitored for bleeding, complications, and other side effects

Who May Be Eligible (Plain English)

Who May Qualify:• Patients aged 18 to 80 years - Both male or female patients - Patients who have undergone emergent exploratory laparotomy for any reason whether traumatic or non-traumatic - Patients with expected immobility for more than 24 hours Who Should NOT Join This Trial: - Patients with diagnosed pre-operative DVT - BMI more than 40 - Patient who are on mechanical ventilation post operatively - Patient with postoperative Myocardial infarction, ischemic heart disease or cerebrovascular accident - Patients who have undergone limb surgery in addition to exploratory laparotomy Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria:• Patients aged 18 to 80 years * Both male or female patients * Patients who have undergone emergent exploratory laparotomy for any reason whether traumatic or non-traumatic * Patients with expected immobility for more than 24 hours Exclusion Criteria: * Patients with diagnosed pre-operative DVT * BMI more than 40 * Patient who are on mechanical ventilation post operatively * Patient with postoperative Myocardial infarction, ischemic heart disease or cerebrovascular accident * Patients who have undergone limb surgery in addition to exploratory laparotomy

Treatments Being Tested

DRUG

rivaroxaban (10mg)

Name: Drug: Rivaroxaban Type: Drug Description: Participants receive rivaroxaban 10 mg orally once daily for 7 days following emergency exploratory laparotomy. All patients also receive standard perioperative management and mechanical prophylaxis as per institutional guidelines.

DRUG

Enoxaparin 40 mg SC

Name: Drug: Enoxaparin Type: Drug Description: Participants receive enoxaparin 40 mg subcutaneously once daily for 7 days following emergency exploratory laparotomy. All patients also receive standard perioperative management and mechanical prophylaxis as per institutional guidelines.

Locations (1)

Mayo Hospital Lahore
Lahore, Punjab Province, Pakistan